USA - NASDAQ:ISPC - US45032V2079 - Common Stock
The current stock price of ISPC is 0.7704 USD. In the past month the price decreased by -34.73%. In the past year, price decreased by -81.5%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 38.26 | 46.72B | ||
| DOCS | DOXIMITY INC-CLASS A | 44.17 | 12.33B | ||
| WAY | WAYSTAR HOLDING CORP | 33.39 | 7.07B | ||
| HTFL | HEARTFLOW INC | N/A | 3.05B | ||
| CERT | CERTARA INC | 23.18 | 1.82B | ||
| SDGR | SCHRODINGER INC | N/A | 1.51B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.54B | ||
| PHR | PHREESIA INC | N/A | 1.36B | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 9.8 | 1.19B | ||
| CTEV | CLARITEV CORP | N/A | 1.09B | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.08B | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | N/A | 896.76M |
iSpecimen, Inc. is a healthcare organization that engages in procurement of human biospecimen. The company is headquartered in Woburn, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2021-06-17. The firm addresses a critical challenge, which focuses on connecting life science researchers who need human biofluids, tissues, and living cells (biospecimens) for their research. The Company’s iSpecimen Marketplace platform is designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery. Its technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. In addition to providing the technology platform to connect researchers and healthcare providers, the Company handles all marketing, sales, contracting, and compliance functions across both sides of the marketplace. The iSpecimen Marketplace technology comprises four functional areas: search, workflow, data and administrative, compliance and reporting.
ISPECIMEN INC
8 Cabot Road, Suite 1800
Woburn MASSACHUSETTS US
CEO: Christopher Ianelli
Employees: 24
Phone: 17813016700
iSpecimen, Inc. is a healthcare organization that engages in procurement of human biospecimen. The company is headquartered in Woburn, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2021-06-17. The firm addresses a critical challenge, which focuses on connecting life science researchers who need human biofluids, tissues, and living cells (biospecimens) for their research. The Company’s iSpecimen Marketplace platform is designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery. Its technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. In addition to providing the technology platform to connect researchers and healthcare providers, the Company handles all marketing, sales, contracting, and compliance functions across both sides of the marketplace. The iSpecimen Marketplace technology comprises four functional areas: search, workflow, data and administrative, compliance and reporting.
The current stock price of ISPC is 0.7704 USD. The price decreased by -4.04% in the last trading session.
ISPC does not pay a dividend.
ISPC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ISPC.
The Revenue of ISPECIMEN INC (ISPC) is expected to grow by 11.76% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
ISPECIMEN INC (ISPC) currently has 24 employees.
ChartMill assigns a fundamental rating of 2 / 10 to ISPC. ISPC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months ISPC reported a non-GAAP Earnings per Share(EPS) of -8.57. The EPS increased by 49.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -168.9% | ||
| ROE | -1638.63% | ||
| Debt/Equity | 0 |
For the next year, analysts expect an EPS growth of 10.23% and a revenue growth 11.76% for ISPC